Toronto Dominion Bank bought a new position in Palvella Therapeutics (NASDAQ:PVLA - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 13,211 shares of the company's stock, valued at approximately $159,000. Toronto Dominion Bank owned approximately 0.12% of Palvella Therapeutics at the end of the most recent reporting period.
A number of other large investors have also made changes to their positions in the company. Renaissance Technologies LLC acquired a new position in Palvella Therapeutics in the 4th quarter worth approximately $256,000. BML Capital Management LLC acquired a new stake in shares of Palvella Therapeutics in the fourth quarter worth $506,000. Geode Capital Management LLC acquired a new position in Palvella Therapeutics during the fourth quarter valued at $171,000. Nantahala Capital Management LLC purchased a new position in Palvella Therapeutics during the 4th quarter valued at about $3,001,000. Finally, Adams Street Partners LLC purchased a new position in shares of Palvella Therapeutics during the 4th quarter valued at $4,916,000. Institutional investors and hedge funds own 40.11% of the company's stock.
Palvella Therapeutics Trading Down 0.2%
Palvella Therapeutics stock traded down $0.05 during trading hours on Friday, reaching $24.73. 11,079 shares of the company were exchanged, compared to its average volume of 67,407. Palvella Therapeutics has a 12 month low of $6.20 and a 12 month high of $29.27. The firm has a 50-day moving average price of $23.80. The firm has a market capitalization of $273.41 million, a price-to-earnings ratio of -2.04 and a beta of 0.10.
Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.40) by $2.66. Equities research analysts forecast that Palvella Therapeutics will post -3.69 earnings per share for the current fiscal year.
Insiders Place Their Bets
In related news, Director George M. Jenkins acquired 2,500 shares of the company's stock in a transaction dated Wednesday, April 9th. The shares were bought at an average price of $20.13 per share, for a total transaction of $50,325.00. Following the acquisition, the director now owns 183,171 shares in the company, valued at $3,687,232.23. This trade represents a 1.38% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 20.50% of the company's stock.
Wall Street Analyst Weigh In
PVLA has been the topic of several research reports. Jones Trading started coverage on Palvella Therapeutics in a research report on Tuesday, March 25th. They issued a "buy" rating and a $45.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and set a $38.00 price objective on shares of Palvella Therapeutics in a research report on Wednesday, April 30th. TD Cowen initiated coverage on shares of Palvella Therapeutics in a research note on Wednesday, February 5th. They issued a "buy" rating and a $44.00 target price for the company. Scotiabank began coverage on shares of Palvella Therapeutics in a research report on Friday, March 7th. They issued a "sector outperform" rating and a $50.00 target price for the company. Finally, Canaccord Genuity Group cut their price target on shares of Palvella Therapeutics from $53.00 to $52.00 and set a "buy" rating on the stock in a report on Friday, May 16th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $46.29.
View Our Latest Analysis on Palvella Therapeutics
Palvella Therapeutics Company Profile
(
Free Report)
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.
Further Reading
Before you consider Palvella Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Palvella Therapeutics wasn't on the list.
While Palvella Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
